Addison's Disease treatment Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Global Addison's Disease Treatment Market is segmented by drug class (Glucocorticoid, Mineralocorticoid, and Others), route of administration (Oral, Parenteral, and Others), diagnosis (Laboratory Testing and Imaging Testing), end-user (Hospitals, Homecare, Specialty Clinics, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

addison's disease treatment market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Addison's Disease Treatment market is projected to register a CAGR of 4.1% during the forecast period (2022 - 2027).

COVID-19 pandemic has significantly impacted Addison's disease, a rare disease treatment market. The rise in COVID-19 cases has led to global healthcare services shifting their resources toward COVID-19 care while impacting patients with rare diseases. According to the Eurordis International Survey, rare disease patients seemed to have a worse experience than chronic disease patients due to the pandemic. According to the study published by the National Center for Biotechnology Information in 2021, it has been found that the adrenal system is one of the most highly affected organ systems in the body during acute active infection in individuals with COVID-19 infection who require hospitalization. The pandemic led to the shutdown of companies and other non-healthcare businesses. The lack of healthcare services and canceled/postponed appointments result in the underdiagnosis of rare disease patients, negatively impacting the market.

The factors propelling the market's growth are rising incidences of Addison's disease globally, growing awareness regarding adrenal insufficiency, and rising healthcare expenditure in the countries.

The rising incidences of Addison's disease are the key factor driving the market's growth over the forecast period. According to an article published by the National Center for Biotechnology Information in 2021, titled "Adrenal Insufficiency in Patients," it has been found that one in 10,000 newborns are affected by congenital adrenal hyperplasia, an inherited form of primary adrenal insufficiency. In addition, the increasing number of tuberculosis cases is also causing adrenal insufficiency disease among people. According to the statistics published by the Centers for Disease Control 2021, 7,860 cases of tuberculosis were reported in the United States in 2021. In addition, about 13 million in the United States are affected by latent tuberculosis infection.

However, the high costs associated with the treatment medications, the lack of awareness among people regarding Addison's disease, and the inability to diagnose the disease early are likely to hinder the market's growth.

Scope of the Report

As per the report's scope, Addison's disease is a rare disorder in which the adrenal cortex fails to produce adequate glucocorticoids and mineralocorticoids to meet metabolic demands (primary adrenocortical insufficiency). The loss or primary dysfunction of the adrenal glands. The Global Addison's Disease Treatment Market is segmented by drug class ( Glucocorticoid, Mineralocorticoid, and Others), route of administration ( Oral, Parenteral, and Others), diagnosis (Laboratory Testing and Imaging Testing), end-user (Hospitals, Homecare, Specialty Clinics, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (USD million) for the above segments.

By Drug Class
Glucocorticoid
Mineralocorticoid
Others
By Route of Administration
Oral
Parenteral
Others
By Diagnosis
Laboratory Testing
Imaging Testing
By End-user
Hospitals
Homecare
Specialty Clinics
Others
Geography
North America
Europe
Asia-Pacific
Middle East and Africa
South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oral Route is Expected to Have the Significant Market Share

The factors propelling the growth of the oral segment are easy to top consume and are better replacement therapy for the disease.

The most common oral drugs used for the treatment include corticosteroids such as hydrocortisone, prednisone, or methylprednisone, and fludrocortisone acetate, which replaces the cortisol and aldosterone in the body, which the body lacks to produce. According to the study published by the National Center for Biotechnology Information in 2020, it has been observed that oral hydrocortisone and fludrocortisone are found to have the potential to simulate the physiological serum cortisol level in the body.

In addition, the increasing number of tuberculosis cases is also causing adrenal tuberculosis, leading to adrenal insufficiencies in patients, likely increasing the demand for disease treatment. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, and anti-tuberculosis medication.

Moreover, the company focusing on developing oral medications for treating patients with Addison's disease is also likely to increase the market growth over the forecast period. For instance, in February 2022, Diurnal announced that the first patient was dosed in its phase II European clinical trial of modified-release hydrocortisone for treating people with adrenal insufficiency (AI), also known as Addison’s disease.

addison's disease treatment market share

North America is Expected to Have the Significant Market Share

North America is anticipated to have a significant share, owing to the factors such as increasing disease instances in the region, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure.

The increasing number of tuberculosis or adrenal tuberculosis cases causes adrenal insufficiency in patients by destructing the adrenal cortex and hypertrophy of the adrenal glands with caseating granulomas, thus, increasing the demand for better treatment in the region. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, or anti-tuberculosis medication. According to the statistics published by the Centers for Disease Control, in 2021, it has been found that 35.8% of Non-Hispanic Asian persons, 29.7% of Hispanic people, and 11% of Non-Hispanic White people have tuberculosis disease in the United States.

Moreover, the increasing research and development activities and increasing focus of the companies in developing treatments for Addison's disease is further boosting the market's growth in the region. For instance, in January 2022, Antares Pharma announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. ATRS-1902 is being developed to treat acute adrenal insufficiency, an adrenal crisis, in adults and adolescents.

addison's disease treatment industry

Competitive Landscape

Addison's disease treatment market is moderately competitive with many players. The players focus on developing drugs to treat the disease and withhold their position in the market. Some key players are Bristol-Myers Squibb Company, Merck KGaA, Sandoz International GmbH, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Recent Development

In January 2022, Antares Pharma announced that the United States Food and Drug Administration had granted Fast Track designation for ATRS-1902 for adrenal crisis rescue in adults and adolescents using the company's Vai novel proprietary auto-injector platform to deliver a stable liquid formulation of hydrocortisone.

In September 2021, Diurnal Group launched Efmody hydrocortisone modified-release hard capsules) in the United Kingdom, for the treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH).

In August 2021, Eton Pharmaceuticals acquired the United States and Canadian rights to ZENEO Hydrocortisone autoinjector. The product is expected to be submitted to the Food and drug administration in 2023. It will be the first needle-free autoinjector for the treatment of adrenal crisis.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidences of Addison's Disease

      2. 4.2.2 Growing Awareness about the Addison's Disease and Rising Healthcare Expenditure

    3. 4.3 Market Restraints

      1. 4.3.1 Inability to Diagnose the Disease in Early Stages

      2. 4.3.2 High Costs Associated with the Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Glucocorticoid

      2. 5.1.2 Mineralocorticoid

      3. 5.1.3 Others

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Parenteral

      3. 5.2.3 Others

    3. 5.3 By Diagnosis

      1. 5.3.1 Laboratory Testing

      2. 5.3.2 Imaging Testing

    4. 5.4 By End-user

      1. 5.4.1 Hospitals

      2. 5.4.2 Homecare

      3. 5.4.3 Specialty Clinics

      4. 5.4.4 Others

    5. 5.5 Geography

      1. 5.5.1 North America

      2. 5.5.2 Europe

      3. 5.5.3 Asia-Pacific

      4. 5.5.4 Middle East and Africa

      5. 5.5.5 South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol-Myers Squibb Company

      2. 6.1.2 Merck KGaA

      3. 6.1.3 Sandoz International GmbH

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Takeda Pharmaceutical Company Limited

      6. 6.1.6 GlaxoSmithKline plc

      7. 6.1.7 Abbott

      8. 6.1.8 Amgen Inc.

      9. 6.1.9 Bayer AG

      10. 6.1.10 Eli Lilly and Company

      11. 6.1.11 Biogen

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Addison's Disease treatment Market market is studied from 2019 - 2027.

The Global Addison's Disease treatment Market is growing at a CAGR of 4.1% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Takeda Pharmaceutical Company Limited, Merck KGaA, Sandoz International GmbH, Pfizer Inc., Bristol-Myers Squibb Company are the major companies operating in Global Addison's Disease treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!